State Board of Administration of Florida Retirement System bought a new position in 2seventy bio, Inc. (NASDAQ:TSVT – Get Rating) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 14,253 shares of the company’s stock, valued at approximately $188,000.
Other hedge funds have also bought and sold shares of the company. Metropolitan Life Insurance Co NY purchased a new position in 2seventy bio in the 1st quarter worth about $25,000. Ameritas Investment Partners Inc. purchased a new stake in shares of 2seventy bio during the 1st quarter valued at about $30,000. Amalgamated Bank purchased a new stake in shares of 2seventy bio during the 1st quarter valued at about $46,000. International Biotechnology Trust PLC purchased a new stake in shares of 2seventy bio during the 1st quarter valued at about $94,000. Finally, Group One Trading L.P. purchased a new stake in shares of 2seventy bio during the 1st quarter valued at about $69,000. Hedge funds and other institutional investors own 91.47% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on the stock. SVB Leerink reduced their price target on shares of 2seventy bio from $42.00 to $41.00 and set an “outperform” rating for the company in a research report on Tuesday, November 8th. Guggenheim assumed coverage on shares of 2seventy bio in a research report on Monday, October 31st. They set a “buy” rating and a $30.00 price target for the company. Morgan Stanley upped their price target on shares of 2seventy bio from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Tuesday, November 8th. Finally, Canaccord Genuity Group reduced their price target on shares of 2seventy bio from $42.00 to $28.00 in a research report on Friday, August 12th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $30.80.
2seventy bio Trading Up 10.0 %
2seventy bio Company Profile
2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma.
- Get a free copy of the StockNews.com research report on 2seventy bio (TSVT)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
Receive News & Ratings for 2seventy bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 2seventy bio and related companies with MarketBeat.com's FREE daily email newsletter.